Intraday Info: Sierra Oncology Inc (NASDAQ:SRRA) locked on 07/02/2017 at $1.44. It has average volume 399,079 whilst it totals volume 119,017. The company has EPS -1.66 and according to analysts next quarter EPS and next year estimate EPS will -0.27 and -1.17 respectively.
Ownership Summary: Sierra Oncology Inc has total institutional ownership 34.93% while its total outstanding shares 30 millions that’s value of holdings $15 million.
Active Positions: In the latest year, SRRA 22 holders have raised its positions while it contains total 1,579,955 shares. And the strength of reduced positions holders and held positions holders are 20 and 12 respectively.
New and Sold Out Positions: In SRRA force of new positions holders 9 and it has total shares 859,526. And force of sold out positions holders 13 and it has 2,695,516 shares.
Comparison with Other Company: The Market Value of SRRA is $43,668 below from AbbVie Inc. market value which is $98M. Current Last Sale of SRRA is $1.44 below from ABBV current last sale which is $60.56.
Sierra Oncology, Inc. a medical level drug development corporation centered on advancing subsequent era DNA damage reaction (DDR) therapeutics for the treatment of sufferers with most cancers, recently declared that it has efficaciously transferred sponsorship of the 2 ongoing segment 1 clinical trials comparing its Checkpoint kinase 1 (Chk1) inhibitor, SRA737, from the cancer studies united kingdom Centre for Drug improvement to the employer. According with the license agreement for SRA737, a $2.zero million fee is because of CRT Pioneer Fund LP for the fulfillment of this milestone.
“SRA737 objectives Chk1, a key mobile cycle checkpoint and imperative regulator of the DDR community, an thrilling rising goal in oncology that has broad clinical and business capability,” said Dr. Nick Glover, President and CEO of Sierra Oncology. “we are glad to claim that the formal transfer of sponsorship to Sierra Oncology of these two actively recruiting medical trials was done as deliberate and beforehand of plan. Our intention is to offer a replace from those research within 12 months a good way to in addition tell our development method.”
Sierra Oncology, Inc. engages in growing DNA harm response (DDR) therapeutics for the treatment of sufferers with cancer. Its lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key mobile cycle checkpoint and principal regulator of the DDR community. The organization engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase present process preclinical development. The agency was previously referred to as ProNAi Therapeutics, Inc. and modified its name to Sierra Oncology, Inc. in January 2017.